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 Abstract 
Mechanisms regulating protein degradation ensure the correct and timely expression of 
transcription factors such as hypoxia inducible factor (HIF). Under normal oxygen tensions, 
HIFα subunits are targeted for proteasomal degradation mainly by vHL-dependent 
ubiquitination. Deubiquitinases are responsible for reversing this process. While the 
mechanism and regulation of HIFα ubiquitin-dependent proteasomal degradation has been 
the object of many studies, little is known about the role of deubiquitinases. Here we show 
that HIF2α expression is regulated by the deubiquitinase Cezanne in an E2F1-dependent 
manner. Knockdown of Cezanne down-regulates HIF2α mRNA, protein and activity 
independently of hypoxia and proteasomal degradation. Mechanistically, HIF2α gene 
expression is controlled directly by E2F1, and Cezanne regulates the stability of E2F1. 
Exogenous E2F1 can rescue HIF2α transcript and protein expression, when Cezanne is 
depleted. Together these data reveal a novel mechanism for the regulation of HIF2α 
expression, demonstrating that HIF2α promoter is regulated by E2F1 directly and that 
Cezanne regulates HIF2α expression via control of E2F1 levels. Our results thus suggest that 
HIF2 is controlled transcriptionally in a cell cycle dependent manner and in response to 
oncogenic signalling. 
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 Introduction 
Adaptation to changes in the microenvironment requires a tight regulation of gene 
expression. In response to low oxygen levels, gene expression is mainly regulated by the 
Hypoxia Inducible Factor (HIF) family of transcription factors, which enact a transcriptional 
programme to allow cell survival as well as the re-establishment of oxygen supply. The de-
regulation of HIF signalling has severe implications on several disease processes, including 
stroke, tissue regeneration and cancer (Semenza, 2012).  
HIF is a heterodimeric transcription factor composed by one of three oxygen-labile α 
subunits (HIF1α, 2α or 3α) and an oxygen-insensitive β subunit. So far, most studies 
regarding HIF regulation have been directed towards HIF1α and little is known about how 
the other subunits are modulated. Interestingly, although HIF1α and 2α share sequence 
similarity and a number of transcriptional targets, the tissue distribution and functional 
properties of the two proteins are significantly different (Chiavarina et al., 2012; Gordan et 
al., 2007a). Furthermore, HIF2α has been associated with tumour promoting properties in 
different types of tumours (Bangoura et al., 2007; Chiavarina et al., 2012; Holmquist-
Mengelbier et al., 2006; Noguera et al., 2009; Raval et al., 2005; Scrideli et al., 2007).  
HIF regulation by oxygen impacts on the protein stability of the α subunits and is 
dependent on the activities of a class of dioxygenase enzymes called prolyl hydroxylases 
(PHDs). Under normal oxygen tensions PHDs catalyse the hydroxylation of two prolyl 
residues on HIFα subunits in the ODD (oxygen-dependent degradation) domain (Fandrey et 
al., 2006). Prolyl-hydroxylation then attracts the von Hippel-Lindau (vHL) tumor suppressor 
protein, which recruits the Elongin C-Elongin B-Cullin 2-E3-ubiquitin-ligase complex, leading 
to predicted Lys48-linked poly-ubiquitination and proteasomal degradation of HIFα (Ivan et 
al., 2001; Jaakkola et al., 2001; Yu et al., 2001). In hypoxic conditions, PHDs, that require 
molecular oxygen as a co-factor, become inactive allowing HIFα protein stability, 
dimerization with HIF1β and activation of transcriptional targets. More recently, additional 
degradation mechanisms have been described for HIFα subunits (Bento et al., 2010; Bremm 
et al., 2014; Hubbi et al., 2013; Li et al., 2007; Liu et al., 2014) emphasising the complexity of 
HIF homeostasis.  
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 Deubiquitinases (DUBs) are enzymes that can contribute to the stabilisation of target 
proteins through the hydrolysis of ubiquitin chains, and many DUBs associate with E3 ligase 
complexes to fine-tune the ubiquitination status of a common substrate (Komander et al., 
2009). Although DUBs are starting to emerge as attractive therapeutic targets for diseases 
associated with deregulated protein expression levels, such as cancer (Fraile et al., 2012; Pal 
et al., 2014), little is known so far about the role of DUBs in the regulation of the HIF system. 
The ubiquitin specific proteases (USPs) USP20 and USP8 where shown to deubiquitinate 
HIF1α (Li et al., 2005; Li et al., 2002; Troilo et al., 2014), while USP19 stabilises HIF1α in a 
non-catalytic manner (Altun et al., 2012; Bett et al., 2013) and USP52 is required for HIF1α 
mRNA stability (Bett et al., 2013). Additionally, we have recently demonstrated that the 
ovarian tumour protease (OTU) DUB Cezanne (OTUD7B) binds to and regulates the turnover 
of HIF1α thereby modulating HIF1 transcriptional activity (Bremm et al., 2014). However, 
there is no information on whether or how DUBs alter HIF2 protein.  
Here we report that Cezanne regulates HIF2α expression and activity by modulation 
of the HIF2α gene expression. We show that Cezanne regulates E2F1 protein levels and that 
E2F1 is required for HIF2α gene expression, by directly binding to the HIF2 promoter. 
Furthermore, we demonstrate that the regulation of HIF2α by Cezanne is E2F1 dependent 
and that Cezanne depletion impairs normal cell cycle progression and increases cell death. 
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 Results 
The majority of research concerning the regulation of HIFs has been directed 
towards HIF1. HIF1 is decorated by many post-translation modifications such as 
hydroxylation, sumoylation, ubiquitination, nitrosylation, phosphorylation, however 
whether all of these are also present in HIF2 is currently unknown. In addition, 
mechanisms controlling HIF1 gene transcription and translation have also been described 
(Linehan et al., 2010; Rius et al., 2008; van Uden et al., 2008). In contrast, very little 
information exists on how HIF2 expression is controlled, apart from the canonical PHD-vHL 
degradation axis. Recently, we have found that HIF1α is regulated at the protein levels by 
the deubiquinase enzyme OTUD7B/Cezanne (Bremm et al., 2014). Since currently, no DUB 
has been identified to regulate HIF2α, and considering the growing importance of DUBs in 
cancer we decided to investigate if Cezanne alters HIF2 levels and function. 
siRNA-mediated silencing of Cezanne results in decreased HIF2α protein expression 
To determine if Cezanne alters HIF2α expression in cells, we employed a loss of 
function approach using siRNA mediated knockdown. HeLa cells were transfected with a 
specific siRNA for Cezanne for 48h and incubated for 24h at 1% O2 to allow HIF2α protein 
stabilisation prior to harvesting. Under these conditions, we could observe a clear and 
consistent reduction in HIF2α protein levels. The same effect could also be observed in the 
renal cancer cell line 786-O, a renal cancer cell line that only expresses HIF2 and not HIF1 
(Shen et al., 2011), (Figure 1A). In 786-O, the analysis was performed under normal oxygen 
conditions, since these cells are vHL-negative and consequently express high levels of HIF2α 
in normoxia (Shen et al., 2011). We further tested if the observed decrease in HIF2α levels 
correlated with decreased HIF activity. Co-transfecting 786-O cells, with an Hypoxia 
Responsive Element (HRE)-luciferase reporter, we could observe that there was a significant 
reduction in HIF activity in cells depleted of Cezanne, as shown in Figure 1B. Additionally, 
both 786-O and HeLa cells showed reduced levels of known HIF targets such as Glut1, PHD3 
or BNIP3 (Figure 1C). These results were also obtained with a different siRNA against 
Cezanne (Sup. Figure S1A), indicating that reduction of HIF2 levels following Cezanne 
depletion is not a result of siRNA off target effects. Furthermore, when we performed gain 
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 of function experiments, where increasing concentrations of Cezanne were transfected into 
cells, HIF2 levels were concomitantly increased (Figure 1D). 
Cezanne has been associated with hydrolysis of K11-linked ubiquitin chains (Bremm 
and Komander, 2011; Bremm et al., 2014), and HIF2 is known to be regulated by the 
proteasome (Sup. Figure S1B), as such we next tested if Cezanne depletion was inducing 
excessive proteasomal degradation of HIF2α. To this end, cells depleted of Cezanne were 
treated with MG132, as well as DFX or DMOG, two PHD inhibitors, in hypoxia and levels of 
HIF2 were analysed. Interestingly, none of these treatments were able to rescue HIF2α 
levels, when Cezanne was depleted (Figure 1E). Together, these data suggest that HIF2α is 
regulated by Cezanne in a PHD, and proteasomal-independent manner. Interestingly, vHL 
inactivation was also unable to rescue Cezanne’s reduction of HIF2, observed in 786-0 cells 
and RCC4 (data not shown). This suggests that the mechanism by which Cezanne alters 
HIF2 levels is distinct from the mechanism by which Cezanne targets HIF1, where we 
previously observed a clear dependence on vHL (Bremm et al., 2014). 
 
siRNA-mediated silencing of Cezanne regulates HIF2α transcript levels 
HIF1α can be regulated at the transcriptional and translational level independently 
of PHD and vHL activity (Linehan et al., 2010; Rius et al., 2008; van Uden et al., 2008). Given 
our results above, we next investigated whether Cezanne depletion had an effect on HIF2α 
gene expression. We could observe a marked and significant reduction in HIF2α mRNA in 
cells depleted of Cezanne, independently of hypoxia, in both HeLa and 786-O cells (Figure 
2A). 
Given that little is known about the regulation of the HIF2 gene, we performed a 
bioinformatics analysis of the HIF2α promoter to identify potential binding sites for 
transcription factors (Figure 2B). This analysis identified several binding sites for 
transcription factors such as NF-B, E2F1 and SP1 (Figure 2B). To determine if Cezanne 
down regulation was affecting the expression of any of these transcription factors, Western 
blot analysis was performed. While we could not detect any significant changes in the levels 
of SP1 or NF-B subunits such as p52 (NF-B), depletion of Cezanne resulted in a reduction 
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 in E2F1 protein levels (Figure 2C). Similar reduction in E2F1 protein levels was also observed 
when a second siRNA oligonucleotide was used to knockdown Cezanne (Sup. Figure S1A) 
E2F1 regulates HIF2α transcription 
Our results indicated that Cezanne depletion results in a reduction of E2F1, a 
transcription factor predicted bioinformatically to control HIF2α gene expression. To 
investigate if E2F1 can indeed control HIF2α, we next depleted E2F1 and analysed HIF2α 
mRNA levels (Figure 2D). It was possible to observe that the knockdown of E2F1 also 
produced a reduction on the mRNA levels of HIF2α (Figure 2D) but not HIF1. Similar results 
were also observed in additional cell lines such as 786-0, U2OS and HepG2 (data not shown). 
This result suggests that E2F1 can regulate HIF2α transcription. To determine if this occurs 
through a direct mechanism, i.e., E2F1 is present at the promoter region of the HIF2α gene, 
chromatin immunoprecipitation (ChIP) assays, using a specific E2F1 antibody were 
performed. Two sets of primers were designed encompassing the two regions with 
predicted consensus sequences for E2F1. This analysis revealed that E2F1 is present in the 
promoter region of HIF2α, (Figure 2E). Given that we have found E2F1 binding to both of 
these sites in the HIF2 promoter, we next determined the importance of each of these 
sites in controlling transcription of the HIF2 gene. To this end, we performed luciferase 
assays where both sites were present, each of the sites were individually mutated, or in 
combination (Figure 2F). This analysis revealed that when each of the sites was mutated, 
luciferase activity was significantly reduced, indicating that both sites are important. 
Furthermore, mutation of both sites at the same time, does not further decrease luciferase 
activity when compared to the single mutants, further suggesting that both sites are equally 
important for the regulation of the HIF2 promoter (Figure 2F). Taken together this analysis 
demonstrated that E2F1 is important for the direct regulation the HIF2 gene expression. 
Cezanne regulates HIF2α transcription via E2F1 
Our results suggest that Cezanne-dependent stabilisation of E2F1 is required for 
HIF2α expression. To firmly verify this possibility, we overexpressed E2F1 in cells depleted of 
Cezanne. The overexpression of E2F1 was sufficient to restore the levels of E2F1-dependent 
Cyclin E expression (Sup. Figure S1C). Under these conditions, both mRNA and protein levels 
of HIF2α could be rescued (Figure 3A-B). Furthermore, the induction of the HIF targets PHD3 
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 and BNIP3 was also restored (Figure 3A). To further validate these results, we repeated our 
ChIP analysis for the HIF2 promoter, in the presence or absence of Cezanne (Figure 3C). 
This analysis revealed that in the absence of Cezanne there is a reduction in the presence of 
E2F1 at both of the binding sites we had previously identified on the HIF2α promoter. In 
addition, we also analysed the activity of a luciferase construct containing a portion of the 
HIF2 promoter, which includes the -1218 site, in the presence or absence of E2F1 (Figure 
3D). This revealed that depletion of E2F1 reduced promoter activity significantly, and to 
levels very similar to those obtained when we specifically analysed the E2F1 sites (Figure 
2F).  
Cezanne regulates E2F1 protein levels 
The decrease in E2F1 protein levels in cells depleted of Cezanne was also observable 
in 786-O cells (Figure 4A). However, both in HeLa and in 786-O cells, there was no reduction 
in E2F1 mRNA levels (Figure 4B), indicating that Cezanne interferes directly with E2F1 
protein levels. This reduction in E2F1 protein had direct consequences to the expression of 
E2F1 dependent target, Cyclin E, with Cyclin D1 being slightly increased while Cyclin A did 
not change (Figure 4C). This indicates that Cezanne depletion has important implications for 
E2F1 dependent functions in the cell. In addition, we could also determine that 
overexpression of Cezanne induces an increase in E2F1 protein levels while expression of a 
catalytically inactive mutant (Bremm et al., 2014) does not (Figure 4D). 
E2F1 was previously shown to be modified by K11-linked chains, and targeted for 
proteasomal degradation, by the E3 ligase APC/CCdh1 (Budhavarapu et al., 2012). The 
amount of ubiquitinated E2F1 is small, making it difficult to detect in our experiments (Sup. 
Figure S2C). As such, we could not detect the effects of Cezanne on the ubiquinated form of 
E2F1, however, we still attempted Ubiquitin Chain Restriction Analysis (UbiCRest) 
(Hospenthal et al., 2015). This analysis allows the analysis of the effects of the 
deubiquitinase activity of Cezanne in vitro towards E2F1. Although, again, we could not 
detect the ubiquitinated form of E2F1, treatment of the samples with recombinant Cezanne 
resulted in increased levels of E2F1 (Figure 4E). Our data then suggests that E2F1 can be a 
new substrate for Cezanne. In support of this hypothesis, we could observe that E2F1 co-
immunoprecipitated with Cezanne, when E2F1 and Cezanne are overexpressed in HEK 293 
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 cells (Figure 4F). In addition, endogenous E2F1 could also be detected to interact with 
overexpressed Cezanne in cells (Figure 4G). However, E2F1 levels following depletion of 
Cezanne, could not be rescued by proteasomal inhibition (Sup. Figure S2D-F), indicating that 
the degradation pathway, elicited by Cezanne depletion, is distinct to that described for the 
actions of the APC/CCdh1.  
 
Cezanne depletion results in defective cell cycle progression 
Although E2F1 is required for cell cycle progression and also the presence of K11- 
linked chains has been associated with progression through S-phase and mitosis 
(Matsumoto et al., 2010), the role of Cezanne in regulating the cell cycle is still not clear. We 
thus performed cell synchronisation-release experiments in HeLa cells, using a double 
thymidine block treatment to arrest the cells in the G1 phase, and analysing the cell cycle 
profile by flow cytometry. Although, the synchronisation was successful in both control and 
Cezanne depleted cells, progression into S-phase is defective in the absence of Cezanne. 
When compared to siRNA control cells, 4 to 6 hours post-release, Cezanne depleted cells are 
defective in progressing into S-phase, and remain higher in the G1 phase (Figure 5A). A 
similar impairment is also observed in proportion of cell in G2/M phase. These results are 
consistent with a defect in entry into S-phase, when Cezanne is reduced. Depletion of HIF2 
did not change cell cycle progression significantly (Sup. Figure S3A), and co-deletion of 
Cezanne and HIF2, only slightly altered the timing of delay observed in cell cycle 
progression (Figure 5A). 
Interestingly, and in agreement with our previous finding in hypoxia (Bremm et al., 2014), 
Cezanne depleted cells have higher levels of cell death, and increased markers of apoptosis 
in normoxia (Figure 5B), possibly indicating defects in S-phase entry. 
Our analysis revealed that HIF2 is an E2F1 target, suggesting HIF2 expression can 
be regulated through the cell cycle and in response to mitogenic signals. As such, we tested 
if HIF2α mRNA could be induced by growth factors, a known stimulus for cell cycle 
progression. HeLa cells were starved for 24h in medium containing 0.5% FBS and then 
harvested for mRNA analysis at several time points after replenishing cells with full serum. 
Jo
ur
na
l o
f C
el
l S
ci
en
ce
A
cc
ep
te
d 
m
an
us
cr
ip
t
 Interestingly, HIF2α mRNA is strongly induced after 4h of medium replacement indicating a 
role for growth factors in HIF2α regulation (Figure 5C). Cyclin D1 was used as a control for 
growth factor stimulation, and its activation profile is very similar to that of HIF2. These 
data support the hypothesis that Cezanne can regulate HIF2α expression in an E2F1-
dependent manner and suggest that HIF2 is responsive to cell cycle inducers, such as 
mitogenic signals. 
HIF2 has been shown to cooperate with the cell cycle regulator and transcription 
factor c-Myc (Gordan et al., 2007b). On the other hand, E2F1 has been shown to be required 
for Myc-mediated proliferation in a model of lymphoma in mice (Baudino et al., 2003). To 
determine if in a model of Myc-induced lymphoma, such as the Eµ-Myc transgenic mouse, 
HIF2 mRNA is changing, we analysed HIF2 mRNA levels in wildtype and Myc 
overexpressing pre-B and B-cells (Figure 5D). Our analysis revealed that Myc overexpression 
induced very high levels of the E2F1 target Cyclin E, further indicating activation of the E2F 
family of transcription factors in this model (Sup Figure S3B). Interestingly, oncogenic Myc 
signalling in this model resulted in an induction of HIF2 mRNA in both pre-B and B cells 
isolated from Eµ-Myc mice when compared to wild type mice (Figure 5D). These results 
further support our model that engagement of the E2F pathway leads to HIF2 gene 
expression. 
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 Discussion 
The occurrence of hypoxia in many tumours is associated with increased resistance 
to chemo- and radio-therapy and with a poor prognosis (Semenza, 2012). In addition, the 
de-regulated expression of HIF transcription factors has been reported in several tumour 
types and thus far no effective therapies are known to target HIF-dependent effects (Keith 
et al., 2012). Given the range of signalling and metabolic pathways that are regulated by HIF 
and contribute to tumour progression, it is highly relevant to have a more detailed 
understanding of how HIF expression and turnover is regulated. Furthermore, considering 
the specificity and often tumour promoting effects of HIF2 it is necessary to have a better 
understanding of how this subunit is regulated when designing new drugs to target HIF 
activity. 
Here we describe the regulation of HIF2 protein levels and activity by a 
deubiquitinase, Cezanne, and show that Cezanne regulates HIF2 gene expression by 
modulating the protein levels of E2F1, an important transcription factor associated with cell 
cycle progression (Stevens and La Thangue, 2003).  
So far, there is only one report on the regulation of the HIF2α promoter. Wada and 
collaborators reported that HIF2α expression was modulated by SP1 and SP3 during 
adipogenesis (Wada et al., 2006) in an adipocyte cell model. We here show that E2F1 is a 
transcription factor required for the expression of HIF2α in diverse cellular models such as 
HeLa and 786-O cells, indicating that E2F1 may be a general regulator for HIF2α expression. 
This hypothesis is supported by the observation that known activators of E2F1 activity, such 
as growth factors are also capable of inducing HIF2α expression. Our analysis revealed that 
HIF2 mRNA is responsive to oncogenic c-Myc activation in a model of lymphoma. 
Interestingly, when analysing publicly available datasets in human cancer, HIF2 mRNA is 
highly increased in lymphoma (Oncomine). In these analyses, four out of eight datasets 
demonstrated high levels of HIF2 mRNA when compared to normal, non-tumour cells 
(Oncomine). Given, that c-Myc and E2F1 are potent cell cycle regulators, our observations 
additionally imply a yet unexplored cell cycle-dependent regulation of HIF2α gene 
expression.  
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 The observation that Cezanne co-immunoprecipitates with E2F1 and that Cezanne 
depletion decreases the levels of E2F1, while a wild type but not a catalytically inactive 
overexpressed Cezanne construct increased E2F1 protein, suggests that E2F1 is a new 
Cezanne substrate. This is further supported by the report that E2F1 is modified by K11-
linked ubiquitin chains (Budhavarapu et al., 2012). In vivo, Cezanne is known to have 
preference for K11-linked chains (Bremm et al., 2014). We were unable to readily detect 
ubiquinitated E2F1 in untreated cells, suggesting that only a small amount of E2F1 is 
ubiquinated at specific stages of the cell cycle or that this is rapidly degraded. Since 
proteasome inhibition did not rescue E2F1 levels following Cezanne depletion we could not 
stabilise the ubiquitinated form to significant levels either. However, using UbiCRest 
approach towards E2F1, where recombinant Cezanne was added to E2F1 recovered from 
cells, we could again detect increased levels of E2F1, further indicating that E2F1 is a novel 
substrate for Cezanne. 
The role of Cezanne in cell cycle regulation has not been truly explored as of yet and 
an initial report indicated that Cezanne depletion was not associated with proliferation 
defects (Neumann et al., 2010). However, we observed that Cezanne depleted cells cannot 
progress normally through the cell cycle, which is most likely due to the downregulation of 
E2F1 protein levels, and not HIF2. However, given its preferences for K11-linked chains 
(Bremm et al., 2010; Bremm et al., 2014), and the cell cycle distribution of these chains 
(Matsumoto et al., 2010; Meyer and Rape, 2014), it is very likely that additional substrates 
exit in different stages of the cell cycle. Additional approaches using synchronisation 
techniques at different stages of the cell cycle such as mitosis, could help elucidate 
Cezanne’s effect in the cell cycle. 
Although the regulation is HIF2α expression by Cezanne is most likely primarily at the 
transcriptional level, we cannot disregard a direct protein effect. We detected by mass 
spectrometry that Cezanne and HIF2α can exist in a complex (Sup. Figure S4) and so it is 
possible that Cezanne may regulate HIF2α directly, in a manner similar to that described for 
HIF1α (Bremm et al., 2014). However, given the ability of E2F1 to rescue HIF2 levels in the 
absence of Cezanne, this implies the direct regulation of HIF2 by Cezanne is minimal, at 
least in the cells systems we have analysed 
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 Cezanne has been associated with tumour progression namely in breast cancer 
(Pareja et al., 2012) and it has also been linked to de-regulated NF-B signalling in a context 
of inflammation (Enesa et al., 2008; Hu et al., 2013; Luong le et al., 2013). The effect we now 
report on E2F1 protein levels indicates a broader impact of this deubiquitinase in cancer via 
the impact on cell cycle regulation. Together with the regulation of HIF1α expression as we 
previously reported, Cezanne appears to be an attractive new drug target in cancer 
treatment.
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 Materials and Methods 
Cell lines, treatments and transfections 
Human cell lines HeLa and HEK293 were cultured in Dulbecco's Modified Eagle Medium and 
cell line 786-O was cultured in RPMI Medium 1640 (Lonza) supplemented with 10% (v/v) 
foetal bovine serum (Gibco), L-Glutamine (Gibco), 50 U/ml penicillin and 50 μg/ml 
streptomycin (Gibco) at 37°C and 5% CO2. Extracts from murine cells were derived from cohorts 
housed at the CRUK Beatson Institute and covered by University of Glasgow ethical review process 
and project licence PPL60/4181. Wild-type mice used as control. All mice were on C57Bl/6J 
background. CD19 positive cells were isolated from the lymph nodes and pelleted before 
RNA extraction. HeLa-HIF2 promoter cells were generated by transfecting HeLa cells with a 
commercially purchased HIF2 renilla luciferase promoter and a puromycin resistance 
cassette in the ratio of 1:9. Transfected cells were selected using 2 μg/ml puromycin (Sigma) 
48 h after transfection. Once selection was complete, cells were maintained in complete 
DMEM supplemented with 0.5 μg/ml puromycin. 
 
Hypoxia treatment at 1% O2 was achieved using an INVIVO2 hypoxia workstation 
(Ruskinn, Bridgend, Wales). To avoid reoxygenation cells were lysed inside the workstation.  
Proteasome inhibition was achieved by treating cells with 10 µM or 20 µM MG132 
(Merck-Millipore) for 3 or 7 hours (h) as indicated. Two additional proteasomal inhibitors 
were used in Hela cells and the treatments were with 10 µM MLN9708 (Stratech Scientific) 
for 1 h or 2 µM Epoxomicin (Merck-Millipore) for 4 h. 
To inhibit proline hydroxylases cells were treated with DMOG (1  mM final 
concentration) or DFX mesylate (Sigma) was added at a final concentration of 200 µM, for 1 
h 30 minutes (min) and 24 h respectively.  
To test the effect of growth factors on HIF2α expression, HeLa cells were incubated 
for 24 h in medium containing 0.5% of FBS and then harvested at the different time points 
after medium replacement containing 10% FBS. 
siRNA duplex oligonucleotides were synthesized by MWG/Eurofins: Control siRNA 
(5’-CAGUCGCGUUUGCGACUGG-3’); Cezanne (5’-CCGAGUGGCUGAUUCCUAU-3’), HIF2 (5’-
CAGCAUCUUUGACAGU-3’), E2F1 (5’-CGCUAUGAGACCUCACUG-3’).  
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 Plasmids: GFP-Cezanne wildtype and C145S were previously described in (Bremm et 
al., 2014), E2F1-ER plasmid was a kind gift from Dr. Victoria Cowling (Dundee, UK). HRE-
luciferase construct was a kind gift of Prof. Gerry Melino (NIH, USA). Ha-E2F1 (Addgene 
24225) was a gift from Prof. Kristian Helin (Lukas et al., 1996). HIF2a promoter construct was 
obtained from Switchgear genomics. HIF2 E2F1 sites were cloned using KpnI and MluI RE in 
the pGL3-vector luciferase construct (Promega), with the following oligonucleotides: 
E2F1wt 
Forward: 5'-CTGCCCTTTTCCCGCACTCTAGCATCCCCGCCAAAACCAAACA-3' 
Reverse: 5'-CGCGTGTTTGGTTTTGGCGGGGATGCTAGAGTGCGGGAAAAGGGCAGGTAC-3' 
E2F1mut1 (-2447bp): 
Forward: 5'-CTGCCCTCAAAAAGCACTCTAGCATCCCCGCCAAAACCAAACA-3' 
Reverse: 5'-CGCGTGTTTGGTTTTGGCGGGGATGCTAGAGTGCTTTTTGAGGGCAGGTAC-3' 
E2F1mut2 (-1218bp): 
Forward: 5'-CTGCCCTTTTCCCGCACTCTAGCATCCCTAAAACCCACCAAACA-3' 
Reverse: 5'-CGCGTGTTTGGTGGGTTTTAGGGATGCTAGAGTGCGGGAAAAGGGCAGGTAC-3' 
E2F1mut1&2 
Forward: 5'-CTGCCCTCAAAAAGCACTCTAGCATCCCTAAAACCCACCAAACA-3' 
Reverse: 5'-CGCGTGTTTGGTGGGTTTTAGGGATGCTAGAGTGCTTTTTGAGGGCAGGTAC-3' 
 
For siRNA transfections, 2x105 cells were seeded in 6-well plates and transfected 
after 24 h with 30 nM siRNA duplexes using INTERFERin transfection reagent (Polyplus). 
siRNA and DNA co-transfections were performed using 30 nM siRNA plus 1 µg of plasmid, 
using jetPRIME (Polyplus), according to manufacturer’s instructions.  
For immunoprecipitation experiments, 5 μg of plasmid DNA GFP-Cezanne wt was 
transiently transfected with calcium phosphate per 10 cm dish in HEK293 cells, as described 
in (Webster and Perkins, 1999). For gain of function experiments, 1 µg of each plasmid DNA 
GFP-Cezanne (wt or C194S) or E2F1 per 3.5 cm dish was transiently transfected, using 
jetPRIME (Polyplus), according to manufacturer’s instructions.  
Cell cycle analysis was performed following a cell synchronisation-release protocol 
using Thymidine treatments to block cell cycle progression in the G1-S phase of the cell 
cycle. Cells were transfected as described above with either a control or a Cezanne-specific 
siRNA oligonucleotide. 24 h post-transfection, cells were washed 3 times with PBS and 
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 incubated for 19 h with medium supplemented with 2 mM final concentration of Thymidine. 
Next, cells were PBS-washed again and released for 9h in normal growth medium. After a 
second Thymidine incubation for 15 h, cells were once more released and harvested every 2 
h, for a total of 10 h, by trypsin detachment and ethanol fixation and stored at -20°C. Cell 
cycle profile analysis was performed in a Guava® easycyte HT (Milipore) apparatus, using the 
Guava® Cell Cycle Reagent (Milipore 4500-0220), according to manufacturer’s instructions.      
 
Luciferase reporter assay 
2x105 cells were seeded in 6-well plates and co-transfected with 1 µg 30 nM siRNA 
duplexes using INTERFERin transfection reagent (Polyplus). 48h posttransfection cells were 
lysed in 400 µl passive lysis buffer (Promega). For E2F1 sites luciferase, cells were 
transfected with 1 µg of luciferase constructs for 48 h prior to lysis. Luciferase assays were 
performed according to the manufacturer's instructions (Luciferase Assay System, 
Promega). Results were normalised for protein concentration with all experiments being 
performed a minimum of three times before calculating means and standard deviations as 
shown in figures. 
 
Immunoblot 
Cells were lysed in RIPA buffer, 50 mM Tris-HCl (pH 8), 150 mM NaCl, 1%(v/v) NP40, 
0.5% (v/v) Na-deoxycholate, 0.1% (v/v) SDS, 1 tablet/10 ml Complete, Mini, EDTA-free 
protease inhibitors (Roche). SDS-PAGE and immunoblots were carried out using standard 
protocols.  
Antibodies were used as follows: HIF2α (PA1-16510, Thermo Scientific), Cezanne 
(custom antibody, Eurogentec), Beta Actin (3700, Cell signalling), PHD3 (A300-327A, Bethyl 
Labs), BNIP3 (ab10433, Abcam), Glut-1 (53519, Anaspec), p52 (05-361, Merck Millipore) , 
E2F1 (3742, Cell Signalling), SP1 (07-645, Upstate/Millipore), Cyclin D1 (DCS6, Cell 
Signalling), Cyclin E (HE12, Cell Signalling), Cyclin A (C-19, Santa Cruz), GFP (2956, Cell 
Signalling), Cleaved PARP (Asp214) (9541, Cell Signaling), c-myc (9E10, Sigma), p-Chk1 Ser 
345 (2341, Cell Signaling). 
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Immunoprecipitation 
For immunoprecipitation of endogenous E2F1, 293 cells were transiently transfected 
with GFP-Cezanne and subsequently lysed in 200 μl lysis buffer per 10cm dish (10 mM Tris-
HCl (pH 7.5), 150 mM NaCl, 1% (v/v) T-X100, 20% (v/v) glycerol, 1 tablet/10 ml Complete, 
Mini, EDTA-free protease inhibitors (Roche)). 
Cleared cell lysate was rotated overnight at 4°C with 2 μg of anti-E2F1 antibody and 
then for an additional 1 h 30 min after adding protein G sepharose (Generon). Immobilized 
antigene-antibody complex was then washed three times with PBS and eluted in 20 µl laemli 
(2xSDS buffer) buffer. 
For mass spectrometry analysis, 3x10cm dishes of HeLa cells, with an optical 
confluency of 80-90%, were incubated for 24h at 1% O2 prior to harvesting with a detergent 
free lysis buffer (50mM Tris pH8, 150mM NaCl, 2mM EDTA, 1mM DTT). After 15min 
incubation on ice, the lysates were passed through a 25G syringe 5 times and cleared by 
centrifugation. Immunoprecipitation was carried out using an anti-HIF2α antibody (EPAS-1 
(A-5), Santa Cruz).  
The MS (Mass Spectrometry) based immunoprecipitation experiments were done in 
triplicate. Protein preparations were run out on an SDS-PAGE gel, fractionated into 8 
fractions and an in-gel digestion was performed. The samples were reduced and alkylated 
with DTT and iodoacteamide, and digested using sequencing grade trypsin (Roche). The 
resulting peptides were then cleaned over C18, and submitted for mass spectrometric 
analysis. 
The samples were run on the Orbitrap Velos (Thermo Fisher) using a 180 minute 
gradient (10%-40% 80% Acetonitrile/2% Formic Acid). The parent ion scan was 350-1800Da, 
at 60,000 resolution. The MS/MS scan was done with a minimum signal of 5000, default 
charge state of >2, on the top 10 ions, with a normalised collision energy of 35. Dynamic 
exclusion of 120 seconds was utilised.  
The resulting MS raw data was processed using MaxQuant version 1.3.0.3 (Cox and 
Mann, 2008), using the Andromeda search engine against the Uniprot Human database 
(2012). The variable modifications were oxidation (M), deamidation (NQ) and acetylation 
(protein N-terminus), with a fixed modification of carbamidomethyl (C). The peptide and 
protein FDR was set to 0.01. Protein identifications with <2 peptides, identified as 
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 contaminants (as designated by MaxQuant), a PEP value of >0.05 and reversed sequence 
hits were excluded from further analysis.   
 
Immunoprecipitation & UbiCRest of HA-tagged E2F1 
 3  106 HEK293 cells were seeded per 10 cm culture dish and transfected 24 h later 
with 5 µg pCMV-HA-E2F1. Subsequently, cells were lysed in 50 mM Tris-HCl (pH 7.4), 150 
mM NaCl, 1% (v/v) IGEPAL® CA-630, 0.2% (v/v) SDS, 10 mM NaF, 1mM PMSF, 5 mM N-
Etylmaleimide, 1  Complete, EDTA-free protease inhibitors (Roche) and 1 µl/ml Benzonase® 
Nuclease (250 units/µl). Cleared lysates were incubated with 10 µl anti-HA agarose 
conjugate (Sigma-Aldrich #A2095) per sample for 3 h at 4 °C. Beads were washed 3  with 
wash buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl), 1  with DUB buffer (50 mM Tris-HCl 
(pH 7.4), 50 mM NaCl, 5 mM DTT) and equally split in two reaction tubes. 2 µg GST-
Cezanne1-449 was activated by incubation in DUB dilution buffer (150 mM NaCl, 25 mM Tris 
(pH 7.4), 10 mM DTT) for 10 min at room temperature. GST-Cezanne or DUB buffer alone 
(control) was added to immobilised HA-E2F1 and incubated for 1 h at 37 °C. Subsequent 
SDS-PAGE and immunoblots were carried out using standard protocols. 
 
Analysis of gene expression levels by real-time RT-PCR 
RNA was extracted using peqGOLD total RNA kit (Peqlab), according to the 
manufacturer’s instructions, and reverse transcribed using QuantiTect Reverse Transcription 
Kit (Qiagen). For quantitative PCR, Brilliant II Sybr green kit (Statagene/Agilent), including 
specific MX3005P 96 well semi-skirted plates, were used to analyse samples on the 
MX3005P qPCR platform (Stratagene/Agilent). Actin was used as a normalising agent in all 
experiments. The following primers were used for RT-PCR: 
 
Actin 
F: 5’-CTGGGAGTGGGTGGAGGC-3’ 
R: 5’-TCAACTGGTCTCAAGTCAGTG-3’  
HIF2α 
F: 5’-TTTGATGTGGAAACGGATGA-3’ 
R: 5’-GGAACCTGCTCTTGCTGTTC-3’  
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 Cezanne 
F: 5’-ACAATGTCCGATTGGCCAGT-3’ 
R: 5’-ACAGTGGGATCCACTTCACATTC-3’  
Cyclin D1 
F: 5’-AGTCCGTGTGACGTTACTGTTGT-3’ 
R: 5’-CTCCCGCTCCCATTCTCT-3’  
E2F1 
F: 5’-ATGTTTTCCTGTGCCCTGAG-3’ 
R: 5’-ATCTGTGGTGAGGGATGAGG-3’  
 
mActin 
F: 5’-ATGCTCCCCGGGCTGATAT-3’ 
R: 5’-CATAGGAGTCCTTCTGACCCATTC-3’ 
mHIF2 
F:5’-ATCACGGGATTTCTCCTTCC-3’ 
R: 5’-GGTTAAGGAACCCAGGTGCT-3’ 
mCyclin E 
F:5’-CTGGACTCTTCACACAGATGAC-3’ 
R:5’-GCCTATCAACAGCAACCTACA-3’ 
 
Chromatin Immunoprecipitation.  
Chromatin Immunoprecipitation (ChIP) was performed using an adaptation of 
Schumm and colleagues’ method (Schumm et al., 2006). Proteins and chromatin were cross-
linked with 1% formaldehyde at room temperature for 10 min. Glycine was added to a final 
concentration of 0.125 M for 5 min to quench the reaction. Cells were harvested into 400 µl 
of lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl pH8.1, 1 mM PMSF, 1 μg/ml leupeptin, 
1 μg/ml aprotinin) and left on ice for 10 min. Samples were then sonicated at 4°C eight 
times for 15 seconds with a 30 seconds gap between each sonication at 50% amplitude 
(Sonics Vibra-Cell # VCX130). Supernatants were recovered by centrifugation (12,000rpm for 
10 min at 4°C) before 10% of the each sample was stored as input. Remaining samples were 
split into 120 µL aliquots before being diluted 10 fold in dilution buffer (1%Triton X-100, 2 
mM EDTA, 150 mM NaCl, 20 mM Tris-HCl pH 8.1). Diluted samples were pre-cleared for 2 
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 hours at 4°C by incubating with 2 µg of sheared salmon sperm DNA and 20 µl of protein G-
Sepharose (50% slurry). 
Immunoprecipitations were performed overnight on the remaining sample with 2 µg 
of anti-E2F1 antibody, with the addition of Brij 35 detergent to a final concentration of 0.1%. 
Immune complexes were captured by incubation with 40 µl of protein G-Sepharose (50% 
slurry) and 2 µg salmon sperm DNA for 1 h at 4°C. The immunoprecipitates were washed 
sequentially for 5 minutes each at 4°C in Wash Buffer 1 (0.1% SDS, 1% Triton X-100, 2 mM 
EDTA, 20 mM Tris-HCl, pH8.1, 150 mM NaCl), Wash Buffer 2 (0.1% SDS, 1% Triton X-100, 2 
mM EDTA, 20 mM Tris-HCl, pH8.1, 500 mM NaCl), and Wash Buffer 3 (0.25 M LiCl, 1% 
Nonidet P-40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-HCl, pH8.1). Beads were washed 
twice with Tris-EDTA buffer and eluted with 120 µl of Elution Buffer (1% SDS, 0.1M 
NaHCO3). Crosslinks were reversed by incubation with 0.2 M NaCl at 65 °C overnight and 
Proteinase K (20 µg each), 40 mM Tris-HCl pH6.5, and 10 mM EDTA for 1 h at 45°C was used 
to remove protein. DNA was purified using a PCR-product purification kit according to 
manufacturer’s instructions (NBS Biologicals #NBS363). 3µl DNA was used for qPCR with the 
following primers for the HIF2α promoter (-2447) or (-1218). 
 
HIF2α promoter (-1218) 
F: 5’-CCCTCGCTTTCCAACTTCAA-3’ 
R: 5’- CGCCTACTCTTCCTTCCCTC-3’  
HIF2α promoter (-2447) 
F: 5’- TCTTGAGTGACCCCTCCTTG-3’ 
R: 5’- CTCAAGTGATCTGCCCAACT-3’  
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Figure 1. Cezanne regulates HIF2α protein and activity in a PHD and vHL independent 
manner. A) HeLa and 786-O cells were transfected with either a non-targeting control (ctrl) 
or a Cezanne-targeting siRNA. 24 h after transfection, HeLa cells were exposed to 1% O2 and 
whole cell lysates of both HeLa and 786-O cells were prepared after further 24 h incubation. 
Protein levels of HIF2α and Cezanne were assessed by western blot. The band intensities 
were measured and the values normalised to the control siRNA (p values are significant 
according to the Student’s t test; *** p< 0.001). B) 786-O cells were co-transfected with an 
HRE-luciferase reporter plasmid and each of the siRNAs for 48 h. Results are mean ± 
Standard Deviation (SD) for at least three independent experiments expressed as fold 
activation/repression normalised to those of the control siRNA (p values are significant 
according to the Student’s t test; * p< 0.05, **p < 0.01). C) 786-O cells in basal conditions 
and HeLa cells, either in basal conditions or exposed for 24 h to 1% O2, were transfected 
with control (ctrl) or Cezanne siRNAs and whole cell lysates were prepared 48 h post-
transfection and analysed by western blot with the antibodies depicted. D) HeLa cells were 
transfected with increasing amounts of a GFP-Cezanne wt plasmid, keeping total amount of 
DNA in each transfection constant, and harvested for western blot analysis after 48 h. E) HIF 
proteasomal degradation pathways were inhibited in HeLa cells transfected with control 
(ctrl) or Cezanne siRNAs and exposed to 1% O2 for 24 h, for stabilisation of HIF2α levels.  
Cells were treated with 20 µM MG132 for 3 h (left panel) or 10 µM MG132 for 7 h (right 
panel), 1  mM DMOG for 90 min or 200 µM DFX for 24 h. 
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Figure 2. Cezanne and E2F1 modulate HIF2α expression. A) HeLa and 786-O cells were 
transfected with control (ctrl) or Cezanne siRNAs and whole cell lysates were prepared 48h 
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 post-transfection and total RNA was extracted. RT-qPCR was performed to analyse mRNA 
levels of HIF2α and Cezanne using actin as a normalising gene (p values are significant 
according to the Student’s t test; *** p< 0.001). B) Schematic diagram depicting the 
bioinformatics analysis results for potential transcription factor binding sites in the HIF2 
gene promoter region. C) 786-O cells in basal conditions and HeLa cells exposed for 24 h to 
1% O2, were transfected with control (ctrl) or Cezanne siRNAs and whole cell lysates were 
prepared 48 h post-transfection and analysed by western blot with the antibodies depicted. 
D) HeLa cells were transfected with control (ctrl) or E2F1 siRNAs and 48 h post transfection 
total RNA and protein extracts were prepared. RT-qPCR analysis of HIF2α, HIF1 and E2F1 
mRNA was performed using actin as a normalising gene (p values are significant according to 
the Student’s t test; *** p< 0.001). Protein levels of HIF2α, HIF1, HIF1, and E2F1 under 
the same conditions were also analysed by western blot. E) ChIP were performed in 
untreated HeLa cells using E2F1 and control IgG antibodies. HIF2 promoter regions were 
amplified using specific primers and levels of E2F1 recruitment were analysed by qPCR (p 
values are significant according to the Student’s t test; * p< 0.05). F) 293 cells were 
transfected with 1 µg of each of the indicated luciferase constructs for 48 h prior to lysis and 
luciferase activity analysis (p values are significant according to the Student’s t test; **p < 
0.01, *** p< 0.001). 
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Figure 3. Overexpression of E2F1 rescues HIF2α expression and activity in Cezanne-
depleted cells. A) HeLa cells were co-transfected with 30 nM of either control (ctrl) or 
Cezanne siRNA plus 1 µg of either empty vector or E2F1 expression plasmid. 24 h after 
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 transfection, cells were exposed to 1% O2 and incubated for further 24 h. Whole cell lysates 
were analysed by western blot with the antibodies depicted. B) Cells were treated as in (A) 
but total RNA was extracted and the mRNA levels HIF2α and Cezanne were determined by 
RT-qPCR (p values are significant according to the Student’s t test; * p<0.05, *** p< 0.001). 
C) HeLa cells were transfected with control (ctrl) or Cezanne siRNAs prior to fixation and 
lysis. ChIP were performed using E2F1 and control IgG antibodies.  HIF2 promoter regions 
were amplified using specific primers and levels of E2F1 recruitment were analysed by qPCR 
(p values are significant according to the Student’s t test; * p< 0.05, **p < 0.01).  D) HeLa-
HIF2 promoter luciferase cells were transfected with 30 nM of either control (ctrl) or 
Cezanne siRNA for 48 h prior to lysis and luciferase activity analysis (p values are significant 
according to the Student’s t test; **p < 0.01). 
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Figure 4. Cezanne regulates E2F1 protein stability. A) HeLa and 786-O cells were 
transfected with either a non-targeting control (ctrl) or a Cezanne-targeting siRNA. 24 h 
after transfection, HeLa cells were exposed to 1% O2 and whole cell lysates of both HeLa and 
786-O cells were prepared after further 24 h incubation and whole cell extracts were 
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 analysed by western blot to assess total levels of E2F1 and Cezanne. The band intensities 
were measured and the values normalised to the control siRNA (p values are significant 
according to the Student’s t test; *** p< 0.001). B) HeLa and 786-O cells were treated as in 
(A) but total RNA was extracted and the transcript levels of E2F1 were analysed by RT-qPCR. 
C) Whole cell extracts from HeLa cells treated as in (A) were analysed by western blot with 
the antibodies depicted. D) HeLa cells were transfected with either a wt or catalytically 
inactive (C194S) GFP-Cezanne construct or with an empty vector and whole cell lysates were 
analysed by western blot for total E2F1 protein levels 48 h post transfection. E) 293 cells 
were transfected with 5 µg of Ha-E2F1 construct for 48 h prior to lysis. Following 
immunoprecipitation with Ha-beads, samples were treated where indicated with 
recombinant Cezanne. Lysates were analysed by western blot with the indicated antibodies. 
F). 293 cells were co-transfected with 5µg of wt GFP-Cezanne and Ha-E2F1 plasmids for 48 h 
prior to lysis. GFP-Cezanne was immunoprecipitated with an anti-GFP antibody and lysates 
analysed by western blot with the indicated antibodies. G) 293 cells were transfected with 
5µg plasmid wt GFP-Cezanne and left to express for 48 h. Cells were then lysed in a mild NP-
40 lysis buffer and GFP-Cezanne was immunoprecipitated with an anti-GFP antibody. Co-
immunoprecipitation of endogenous E2F1 was analysed by western blot as depicted.  
  
Jo
ur
na
l o
f C
el
l S
ci
en
ce
A
cc
ep
te
d 
m
an
us
cr
ip
t
  
 
 
Figure 5. Cezanne depletion causes defects in cell cycle progression and HIF2 mRNA 
responds to mitogenic and oncogenic signals. A) HeLa cells were transfected with control 
(ctrl), Cezanne, or Cezanne and HIF2 siRNAs, prior to harvesting for cell cycle analysis, 
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 using the double thymidine block protocol (p values are significant according to the 
Student’s t test; * p< 0.05, **p < 0.01). B) Left panel, HeLa cells were treated and analysed 
as in (A) and the total percentage of cells across the several time points for control or 
Cezanne depleted conditions was considered (p values are significant according to the 
Student’s t test; *** p < 0.001); right panel, whole cell lysates from HeLa cells transfected 
with either control or Cezanne siRNAs were analysed by western blot with the antibodies 
depicted. C) HeLa cells were grown in reduced serum medium for 24 h and after 
replenishing with medium containing 10% FBS, harvested for mRNA analysis at various time 
points. Cyclin D1 was used as a positive control for growth factor-dependent gene 
expression induction. D) Wild type B lymphocytes and Eµ-Myc derived pre-B and B-cell 
tumours were analysed for HIF2 mRNA levels by RT-qPCR. Graph depicts levels obtained 
for each mouse analysed and compared to wild type levels (p values are significant 
according to the Student’s t test; * p< 0.05).  
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